Please login to the form below

Not currently logged in
Email:
Password:

Hanover Health opens market access practice

New practice will be led by director Jing Wang-Silvanto

HanoverHanover Health, part of the wider Hanover communications and public affairs consultancy group, has created a new market access-focused practice at its London and Brussels hubs.

Adding to the health specialist's three existing practices - Health Communications and UK and European Health Policy and Advocacy - Healthcare Market Access will be led by director Jing Wang-Silvanto.

Wang-Silvanto joins the new practice from WG Access, where she was director for value access strategy and head of health economics, and also brings client-side expertise from Bristol-Myers Squibb, GlaxoSmithKline and Novartis.

Her team will offer pricing and managed access, early access and payer engagement, and health technology assessment support for pharma clients across Europe.

Andrew Harrison, Hanover's managing director of health, said: “Health system finances are squeezed and there is increased need for companies to demonstrate the value of their products and services.

“There are plenty of market access consultancies, but Hanover's ability to join market access with award-winning policy, advocacy and communications campaigns provides a unique offer that can bring change for clients.

“Market Access is a natural extension of Hanover's health work. For a while clients have asked the team to support pricing, health economics and early access work.

“Our growth in health in the UK and internationally, and in communications as well as policy, gives us the confidence to invest in expanding our services.”

Article by
Rebecca Clifford

21st December 2016

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics